Long-Term Effect of Intravitreal Ranibizumab Injection on Choroidal Neovascularization in Age-Related Macular Degeneration
Journal of the Korean Ophthalmological Society
;
: 1359-1364, 2013.
Article
in Korean
| WPRIM
| ID: wpr-93345
ABSTRACT
PURPOSE:
To evaluate long-term efficacy and safety of intravitreal ranibizumab on choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in Korean patients over a 2-year period.METHODS:
Twenty-three eyes of 23 patients who underwent intravitreal ranibizumab injection for secondary CNV in AMD were followed up more than 2 years, and their records were retrospectively investigated. The best corrected visual acuity (BCVA), central macular thickness (CRT) were compared at baseline and at 6, 12, 18 and 24 months after injection.RESULTS:
The mean BCVA (log MAR) was 0.58 +/- 0.36, 0.54 +/- 0.49, 0.59 +/- 0.49, 0.64 +/- 0.51, and 0.61 +/- 0.51 at baseline, 6, 12, 18 and 24 months, respectively (p = 0.332, p = 1.000, p = 0.670, p = 0.697). The mean CRT was 283.75 +/- 61.41 microm, 239.93 +/- 53.12 microm, 244.89 +/- 47.44 microm, 246.36 +/- 55.78, and 244.70 +/- 54.86 at baseline, 6, 12, 18 and 24 months, respectively (p = 0.009, p = 0.036, p = 0.01, p = 0.015). The mean number of injection was 5.96 +/- 2.93 over a 2-year period.CONCLUSIONS:
In Korean patients who underwent intravitreal ranibizumab injection for secondary CNV in AMD, long-term efficacy in diminishing CRT was evident. However, long-term efficacy in increasing visual acuity was not observed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Visual Acuity
/
Retrospective Studies
/
Choroid
/
Choroidal Neovascularization
/
Eye
/
Antibodies, Monoclonal, Humanized
/
Ranibizumab
/
Macular Degeneration
Type of study:
Observational study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS